YMAB Profile
vY-mAbs Therapeutics, Inc. (YMAB) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's lead product candidate is naxitamab, which is currently in Phase 3 clinical trials for the treatment of relapsed or refractory high-risk neuroblastoma.
Y-mAbs Therapeutics was founded in 2015 and is headquartered in New York, NY. The company's approach to developing novel antibody-based therapeutics is based on the concept of precision medicine, which involves tailoring treatments to the specific genetic and molecular characteristics of individual patients.
In addition to naxitamab, Y-mAbs Therapeutics has a pipeline of other product candidates in various stages of development. These include omburtamab, which is being evaluated for the treatment of pediatric central nervous system (CNS) tumors, and the anti-CD20 monoclonal antibody, YMB-002, which is being developed for the treatment of B-cell lymphomas.
Y-mAbs Therapeutics has collaborations with several leading academic institutions, including Memorial Sloan Kettering Cancer Center, The Rockefeller University, and the National Cancer Institute. The company is also focused on expanding its pipeline through the discovery and development of new product candidates using its proprietary antibody discovery platform.
As of September 2021, Y-mAbs Therapeutics had a market capitalization of approximately $2.4 billion.
|
